Drug intelligence / Profile preview

edotreotide

Development stage: Unknown
Lead developer: ITM Isotope Technologies Munich
Modality: Peptides
Administration: Intravenous

Overview

Edotreotide (DOTA-TOC) is an 8-amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). It functions as a somatostatin receptor targeting agent with highest affinity for subtype 2 receptors (sstr2). When labeled with different radioisotopes, it serves various clinical purposes: with gallium-68 for diagnostic PET imaging of neuroendocrine tumors, with yttrium-90 or lutetium-177 for peptide receptor radionuclide therapy (PRRT), and experimentally with bismuth-213 or terbium-161 for enhanced therapeutic effects.

Brand names: SomaKit TOC
Other names: DOTA-(Phe1-Tyr3)-octreotideDOTA0-Phel-Tyr3-octreotideDOTA-0-Phel-Tyr3-octreotideDOTA 0-Phel-Tyr3-octreotide

Targets

SSTR2 (Somatostatin receptor type 2)SSTR1 (Somatostatin Receptor Type 1)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)

Beyond the preview

Go deeper on edotreotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on edotreotide.

Explore the full profile